Medicus Pharma Ltd (NASDAQ: MDCX) is a clinical-stage pharmaceutical company incorporated under the laws of Ontario, Canada, that is developing drug-delivery and therapeutic product candidates, including a dissolving microneedle array platform. The company generates no product revenue as of its fiscal year ended December 31, 2025, and funds operations through equity issuances, including a Standby Equity Purchase Agreement (SEPA) with Yorkville under which it issued 3,677,853 common shares for gross proceeds of $8,706,270 as of December 31, 2025, as well as debenture financing. Cash used in operating activities was $22,776,769 for the year ended December 31, 2025, driven by research and development and general and administrative spending. Key pipeline assets include SkinJect, an investigational dissolving microneedle array (D-MNA) targeting basal cell carcinoma, and Teverelix, with a clinical study planned for 2026. The company is also exploring co-development of thermostable mRNA vaccines with HelixNano using its microneedle delivery platform.

Revenue model

Medicus Pharma has no product revenue as of fiscal year ended December 31, 2025. Funding comes from equity offerings, proceeds under a Standby Equity Purchase Agreement with YA II PN, LTD. (Yorkville), warrant and stock option exercises, and debenture issuances.

Products and services

SkinJect: investigational dissolving microneedle array (D-MNA) for basal cell carcinoma, including an Expanded Access IND program for Gorlin Syndrome patients. Teverelix: a clinical-stage therapeutic candidate with a study planned for 2026. Microneedle array delivery platform under co-development exploration with HelixNano for thermostable mRNA infectious disease vaccines.

Customers and end markets

No commercial customers as of the filing date. Target end markets include dermatology (basal cell carcinoma, Gorlin Syndrome) and, in early exploration, infectious disease vaccines. Physicians and patients are the intended end users upon potential approval.

Value-chain role

Clinical-stage drug developer relying on third-party manufacturers and contract research organizations. Holds IP and development rights while outsourcing manufacturing and, in part, clinical execution. Pursuing regulatory approval pathways including NDA and Expanded Access IND programs with the FDA.

Geographic exposure

Incorporated in Ontario, Canada. Regulatory activities and clinical development pursued in the United States under FDA jurisdiction. Directors and officers reside in Canada and the United States.

Source: SEC 10-K, filed 2026-03-25

Industry: Pharmaceutical Preparations